CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating activities:
Net loss	$ (523,403)	$ (538,392)
Non-cash adjustments reconciling net loss to operating cash flows
Change in fair value on long-term investment	(94)	6,336
Depreciation and amortization expense	3,297	2,038
Amortization of premium and accretion of discounts on investments	(16,480)	(151)
Share-based compensation expense	130,913	124,581
Loss on disposal of property and equipment	0	(294)
Foreign currency adjustments	0	(9,485)
Changes in operating assets and liabilities:
Accounts receivable, net	(13,786)	0
Inventory	(17,136)	0
Other current assets	(3,600)	(8,149)
Other long-term assets	(3,174)	(2,009)
Right-of-use asset	1,056	1,220
Lease liability	(1,282)	4,039
Accounts payable, accrued liabilities and other liabilities	(21,606)	(22,092)
Cash flows used in operating activities	(465,295)	(441,770)
Investing activities:
Purchases of short-term investments	(705,418)	(719,371)
Sales and maturities of short-term investments	854,934	889,918
Purchases of property and equipment	(1,027)	(4,041)
Cash flows provided by investing activities	148,489	166,506
Financing activities:
Proceeds from issuance of common stock and warrants, net of issuance costs	332,515	155,011
Proceeds from issuance of common stock under equity incentive plans	4,427	5,018
Proceeds from issuance of common stock from employee stock purchase plan	3,328	995
Cash flows provided by financing activities	340,270	161,024
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(6)	0
Increase (decrease) in cash, cash equivalents and restricted cash	23,458	(114,240)
Cash, cash equivalents and restricted cash, beginning of period	235,880	413,703
Cash, cash equivalents and restricted cash, end of period	259,338	299,463
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Cash and cash equivalents	258,718	298,843
Restricted cash included in other long-term assets	620	620
Total cash, cash equivalents and restricted cash	259,338	299,463
Supplemental disclosures of non-cash investing activities:
Accrued capital expenditures	$ 0	$ 367